Monday, February 23, 2026

Creating liberating content

Choose your language

hello@global-herald.net

EU won't accept increase...

European Union (EU) leaders said over the weekend that they will not...

China building a different...

The headlines are predictable by now. The United States restricts chip exports....

Asia braces for Trump’s...

TOKYO — Asia has spent the few days since the Supreme Court...
HomePoliticsEuropeNovo Nordisk stock...

Novo Nordisk stock falls as weight loss drug fails to beat Eli Lilly


Novo Nordisk stock fell over 10% Monday after it said its next-generation weight loss drug didn’t meet its primary target.

The drug, CagriSema, didn’t achieve its primary endpoint of demonstrating non-inferiority on weight loss when compared to Eli Lilly‘s rival drug tirzepatide after 84 weeks, Novo said in a statement Monday morning.

Eli Lilly‘s stock rose 2.1% in premarket trading.

Novo is exploring additional trials to test CagriSema, including higher-dose combinations, it said.

This is breaking news. Please refresh for updates.



Source link

Get notified whenever we post something new!

spot_img

Create a website from scratch

Just drag and drop elements in a page to get started with Newspaper Theme.

Continue reading

EU won't accept increase in US tariffs: 'A deal is a deal'

European Union (EU) leaders said over the weekend that they will not accept an increase in U.S. tariffs in the wake of a Supreme Court ruling against some of President Trump's most sweeping tariffs. “The Commission will always...

China building a different AI future than the West

The headlines are predictable by now. The United States restricts chip exports. Chinese labs release competitive models. Pundits declare who is “winning” the artificial intelligence race. The language borrows from sport and war: sprints, breakthroughs and supremacy. It makes...

Enjoy exclusive access to all of our content

Get an online subscription and you can unlock any article you come across.